Why Is RAPPORT THERAPEUTICS Equity (RAPP) Stock Down Today?

Rapport Therapeutics shares fell 17.83% to $22.63 on Wednesday. The decline followed the company’s announcement of a $350 million capital raise, which included separate offerings of common stock and convertible notes.

What Happened

Rapport Therapeutics priced underwritten offerings of common stock and pre-funded warrants alongside $150 million in 2.25% convertible senior notes due 2032. The company also executed a concurrent private placement. The common stock offering was priced at $21.00 per share, while the pre-funded warrants were priced at $20.999. This fundraising package was announced after an initial proposal on October 27. The stock had been relatively stable in the prior week, moving only 1.4% over the last eight sessions before the drop.

What The Data Shows

The stock opened at $20.90, a 24.1% gap down from the prior close of $27.54. Trading volume reached 0.8 million shares, which is 1.5 times the three-month daily average. The session low was $20.75 at 7:05 AM ET, and the high was $23.02 at 9:30 AM ET. Rapport Therapeutics has a market capitalization of $1.2 billion and is unprofitable, with a trailing twelve-month EPS of $3.05. The stock is currently trading below its 52-week range of $23.75 to $52.93. On October 28, the stock printed a fresh 52-week low. Recent insider activity shows six buys totaling $1.7 million and nine sells totaling $6.9 million over the last 90 days. Directors Ramiro Sanchez, John Maraganore, and Paul M. Silva recently purchased shares in late October.

What To Watch

Investors will monitor the completion of the capital raise and the company’s subsequent cash position. The stock’s position relative to its 52-week low and the volume levels during the offering period will be key indicators of market reception.